Home › Stocks › MRK vs BMY
MRK
Merck & Co., Inc.
$119.52
vs
BMY
Bristol-Myers Squibb Company
$55.57

Head-to-Head Comparison

MetricMRKBMY
Market Cap$235.0B$115.0B
P/E Ratio12.08.0
Div YieldN/AN/A
SectorHealthcareHealthcare
Beta0.220.24
RevenueN/AN/A
Net IncomeN/AN/A
EPSN/AN/A

AI Comparison Brief

AI Generated
Verdict
BMY (Bristol-Myers Squibb) is the better investment right now due to its lower price point and slightly higher growth potential in the oncology and immunology sectors. While both stocks present a low beta, indicating lower volatility, BMY offers a more favorable risk/reward profile given its established drug portfolio and ongoing pipeline developments. Investors seeking exposure to the healthcare sector should favor BMY for its combination of growth and relative stability.
Key Differences
  • **Price and Valuation**: BMY's current stock price of $55.57 is significantly lower than MRK's $119.52, making it potentially more attractive for value-focused investors.
  • **Growth Trajectory**: BMY has a robust pipeline, especially in oncology, suggesting strong future revenue growth, whereas MRK's growth prospects are less clear without further details on their product pipeline.
  • **Risk Profile**: Both stocks have low betas, but BMY's slightly higher beta of 0.238 indicates marginally higher volatility, which may appeal to risk-tolerant investors looking for upside.
  • **Market Position**: BMY has a strong competitive position in immunotherapies, while MRK's market position is less defined in the provided data, potentially reflecting a less diversified revenue stream.
Bottom Line
Investors should opt for BMY for its attractive valuation and growth outlook, while MRK may be less appealing without clearer financial metrics. BMY stands out as the preferable choice in the current market environment.
This comparison is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Analysis generated 2026-06-16

Price Chart — MRK vs BMY

Loading chart...
→ Merck & Co., Inc. (MRK) Full Analysis → Bristol-Myers Squibb Company (BMY) Full Analysis ← Stock Screener
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms